Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985181 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL14375488 | 0.72 | MPO (0.42) | MPOABL1HCKSRC | |
| SCHEMBL2488793 | 0.70 | NQO1 (0.74) | SMN1; SMN2LMNANQO1HPGDKDM4E | |
| SCHEMBL8600030 | 0.69 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNABCHENQO1HPGD | |
| SCHEMBL19452835 | 0.68 | — | — | |
| SCHEMBL13400766 | 0.67 | NQO1 (0.61) | SMN1; SMN2LMNANQO1HPGDKDM4E | |
| SCHEMBL10064922 | 0.67 | SLC5A1 (0.57) | SMN1; SMN2LMNATP53POLBHPGD | |
| SCHEMBL23544689 | 0.66 | NQO1 (0.54) | SMN1; SMN2LMNANQO1HPGDKDM4E | |
| SCHEMBL14175640 | 0.66 | NQO1 (0.58) | SMN1; SMN2LMNANQO1HPGDKDM4E | |
| SCHEMBL15201648 | 0.65 | NQO1 (0.64) | SMN1; SMN2LMNANQO1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544396-B2 | Compositions and methods for treating metabolic disease | VOGENX (US) | 2026-02-10 | — | — | US | disclosed |
| CN-114450011-B | Compositions and methods for treating metabolic disorders | 阿沃林特有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20220257624-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | VOGENX | 2022-08-18 | — | — | US | disclosed |
| CN-114450011-A | Compositions and methods for treating metabolic disorders | 阿沃林特有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3976053-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | Avolynt (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544396-B2 | Compositions and methods for treating metabolic disease | SLC5A2, SLC5A1, SLC10A1 | SMN1; SMN2 3128/4885LMNA 3319/4885BCHE 4169/4885 |
| US-20220257624-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | SLC5A2, SLC5A1, SLC10A1 | SMN1; SMN2 3782/4885LMNA 2913/4885BCHE 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.